Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07720206
Starting soon Not applicable

Abnormality of the Central Canal of the Spinal Cord in Syringomyelia in a Patient With a Basal Skull Malformation

NCT07720206 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Bordeaux
Phase
Not applicable
Started
2026-09-30
Last updated
2026-07-22

Condition(s) studied

Chiari Malformation Type ISyringomyelia

Investigational drug(s) / intervention(s)

MRI

MRI: Magnetic Resonance Imaging (MRI) using T1, T2, White-Matter nulled (WMn), and diffusion sequences

Study summary

The aim of this study is to analyze the association between a deformity of the cranial portion of the central spinal canal and syringomyelia in patients with a Chiari-type malformation of the craniocervical junction.

The investigators hypothesize that Chiari malformation, defined by the herniation of the cerebellar tonsils through the foramen magnum, may be responsible for a deformation of the cranial portion of the central spinal canal, and that this deformation is associated with the presence of syringomyelia in patients with this malformation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients being treated for Chiari malformation or syringomyelia at Bordeaux University Hospital * Patients admitted for an initial surgical consultation regarding Chiari malformation with or without syringomyelia at Bordeaux University Hospital * Individuals enrolled in or covered by a social security program. * Free, informed, and express consent (confirmed in writing) (no later than the day of enrollment and prior to any examination required by the study). Exclusion Criteria: * Pregnant or breastfeeding patients * Contraindications to MRI * Individuals deprived of their liberty by judicial or administrative order, * Adults subject to legal protective measures (guardianship, conservatorship, judicial protection). * Patients who have previously undergone surgery for a Chiari malformation or a posterior fossa malformation

Primary outcome measure(s)

  • Deformation of the central canal of the spinal cord — At inclusion (D0)
    The central canal deformation index of the spinal cord, calculated based on the angle of the curves and the length of each segment between two curves.

Trial sites (1)

FacilityCityRegionStatus
Bordeaux university hospital Bordeaux France

More University Hospital, Bordeaux trials in France

TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA Recruiting
3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME) Recruiting
Post-Stroke Secondary Prevention With Digital Monitoring Recruiting
Test and Optimization of New Specific MRI Sequences on an Imager Dedicated to Research Recruiting
Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention Recruiting

Other trials for the same condition

Development of a Patient-reported Outcome Measure for Chiari Malformation and Syringomyelia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07720206 on ClinicalTrials.gov ↗ ← All trials in France